TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • POLE (DNA Polymerase Epsilon) • RUNX1 (RUNX Family Transcription Factor 1) • BAP1 (BRCA1 Associated Protein 1) • ETV6 (ETS Variant Transcription Factor 6) • MLH1 (MutL homolog 1) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • POLD1 (DNA Polymerase Delta 1) • RAD51C (RAD51 paralog C) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • RAD51D (RAD51 paralog D) • DDX41 (DEAD-Box Helicase 41) • GATA2 (GATA Binding Protein 2) • DICER1 (Dicer 1 Ribonuclease III) • FLCN (Folliculin) • PRSS1 (Serine Protease 1) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TXNIP (Thioredoxin Interacting Protein) • ANKRD26 (Ankyrin Repeat Domain Containing 26) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • HOXB13 (Homeobox B13)

TP53 mutation • PTEN deletion

Clinical characterization and genetic analysis of a patient with Xeroderma pigmentosum in conjunct with basal cell carcinoma and melanoma due to variants of XPC gene (PubMed, Zhonghua Yi Xue Yi Chuan Xue Za Zhi)

The c.2391delT(p.F797Lfs*11) and IVS1+1G>A compound heterozygous variants probably underlay the pathogenesis in this patient. The detection of the novel variant has enriched the mutational spectrum of the XPC gene.

5 days ago

Journal

XPC (XPC Complex Subunit, DNA Damage Recognition And Repair Factor)

Thyroid hormone inactivation sustains cancer stem cell maintenance and tumorigenesis in basal cell carcinoma. (PubMed, J Invest Dermatol)

These findings demonstrate that D3 sustains the tumorigenic potential of BCC CSCs by protecting them from TH-induced apoptosis and differentiation. Targeting the D3/TH axis may represent a promising therapeutic strategy to reduce the ability to self-renew of CSCs and inhibit tumor progression in BCC.

6 days ago

Journal

SOX9 (SRY-Box Transcription Factor 9)

Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas (clinicaltrials.gov)

P=N/A, N=60, Recruiting, Roswell Park Cancer Institute | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Apr 2026 --> Dec 2026

7 days ago

Trial completion date • Trial primary completion date

Integrative single-cell analysis uncovers distinct tumour microenvironment ecotypes and immune evasion across skin cancers. (PubMed, Clin Transl Med)

This study establishes a pan-skin cancer immune remodelling framework, providing a foundation for biomarker discovery and the development of new immunotherapy strategies.

7 days ago

Journal • IO biomarker

CXCL10 (Chemokine (C-X-C motif) ligand 10) • SPP1 (Secreted Phosphoprotein 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • NARS2 (Asparaginyl-TRNA Synthetase 2)

Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma (clinicaltrials.gov)

P3, N=142, Recruiting, University of Sao Paulo

9 days ago

New P3 trial

14d

Molecular pathology of rare histologic variants and treatment-resistant lineages of prostate cancer. (PubMed, Urol Oncol)

This review integrates the histopathological, molecular, and emerging spatial transcriptomic insights across this spectrum of rare and treatment-resistant prostate cancer subtypes. By highlighting shared mechanisms such as genomic instability, androgen receptor (AR) pathway bypass, and microenvironmental remodeling, we outline key diagnostic considerations and evolving therapeutic implications relevant to precision oncology.

14 days ago

Review • Journal

TP53 (Tumor protein P53) • AR (Androgen receptor) • HRD (Homologous Recombination Deficiency) • RB1 (RB Transcriptional Corepressor 1)

14d

Contemporary Management of Malignant Eyelid Tumours: Surgical and Immunotherapeutic Advances. (PubMed, Clin Exp Ophthalmol)

Management algorithms are increasingly multidisciplinary, integrating ophthalmology, dermatology, oncology, pathology, and reconstructive surgery. Ongoing challenges include timely detection, management of adverse effects, and the risk of recurrence and metastasis, necessitating long-term surveillance and individualised care.

14 days ago

Review • Journal

PD-1 (Programmed cell death 1)

14d

Multiple Basal Cell Carcinomas in a Long-Term Survivor of Childhood ALL and HSCT-A Call for Dermatologic Vigilance. (PubMed, Life (Basel))

Chemoprevention (e.g., nicotinamide) and targeted therapies (hedgehog inhibitors; Programmed Death-1 blockade) represent key translational levers for care innovation. (5) Integrating structured dermatologic surveillance with molecularly informed prevention and therapy should be standard in survivorship pathways for hematopoietic stem cell transplantation/Radiotherapy-exposed patients.

14 days ago

Review • Journal

PTCH1 (Patched 1)

14d

Immunohistochemical Pattern of CD34 Distribution in Different Types of Basal Cell Carcinoma and in Peritumoral Skin. (PubMed, Medicina (Kaunas))

The transitional zone and uninvolved skin contained CD34-positive fibroblast-like cells situated between secondary bundles of reticular dermis, as well as CD34-positive cell processes within these bundles. The observed pattern of CD34 positivity within the examined regions shows a specific distribution, providing insight into the adaptive responses of the skin to the tumoral process.

14 days ago

Journal

CD34 (CD34 molecule)

16d

SPOTLIGHT 204: Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) (clinicaltrials.gov)

P2, N=60, Active, not recruiting, Highlight Therapeutics | Recruiting --> Active, not recruiting

16 days ago

Enrollment closed

polyinosinic:polycytidylic acid (BO-112)